BNF:

5.1.8

Status:

Red, Green - after consultant/specialist initiation

Decision Date:

None

Comments

RED: 

• Colobreathe dry powder inhaler, 125mg/capsule.  NICE TA276: treating pseudomonas lung infection in cystic fibrosis.  (Decision date - April 2013).
• Promixin for cystic fibrosis patients.  (Decision date - March 2015). 

GREEN after consultant/specialist initiation: see prescribing guidance for nebulised colistimethate injection (Colomycin) in Pseudomonas aeruginosa lung infections in adults with Bronchiectasis (non-Cystic Fibrosis patients).  (Decision date - May 2018).

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again